Yuemin Nan
Hepatology — Third Hospital of Hebei Medical University, China
Yuemin Nan
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Oncology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 254
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| From bystander to key player: The mechanisms and therapeutic potential of IL-24 in liver diseases. liver diseases, cytokines, cells, molecular biology, stress, physiological, neoplasms, liver, research, therapeutics | Mol Biol Rep | 2026 | 0 |
| Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study. hepatitis c, safety, hepatitis b virus, fibrosis, aspartate aminotransferases, coinfection, hepatitis, chronic, transaminases, liver, herpesvirus 1, cercopithecine, sustained virologic response, viruses, hepatitis viruses, therapeutics, blood platelets, hepatitis b, hepatitis b, chronic, infections, hepatitis | J Clin Transl Hepatol | 2026 | 0 |
| Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. liver diseases, thrombopoietin, platelet count, hematology, safety, liver, drug-related side effects and adverse reactions, platelet transfusion, therapeutics, blood platelets, thrombocytopenia | Am J Hematol | 2026 | 0 |
| Development of anticirrhotic drugs from the perspective of the fatty acid metabolism-immune axis: Taking Fuzheng Huayu tablet as an example. liver diseases, pharmaceutical preparations, tablets, fatty acids | Hepatobiliary Pancreat Dis Int | 2026 | 0 |
| [Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure]. liver diseases, cells, genes, acute-on-chronic liver failure, liver, research, therapeutics, liver failure | Zhonghua Gan Zang Bing Za Zhi | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma NCT06272656 — carcinoma, hepatocellular, neoplasms, liver, liver neoplasms, therapeutics, carcinoma | N/A | Recruiting | 2024 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map